Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835807 | 1.00 | GLA (0.41) | GLAMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1163661 | 1.00 | GLA (0.41) | GLAMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL28242504 | 0.90 | GLA (0.36) | GLAMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL12105462 | 0.86 | USP2 (0.38) | GLAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28888385 | 0.86 | USP2 (0.38) | GLAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16584519 | 0.86 | GLA (0.40) | GLAMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL16584521 | 0.86 | GLA (0.40) | GLAMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL16546872 | 0.86 | GLA (0.40) | GLAMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL15152457 | 0.84 | POLB (0.35) | GLATSHRUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL15152458 | 0.84 | POLB (0.35) | GLATSHRUSP2SMN1; SMN2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809024-B2 | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor | ASTRAZENECA AB (SE) | 2014-08-19 | — | — | US | claimed |
| US-20130204012-A1 | Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-08 | — | — | US | claimed |
| WO-2013111158-A2 | PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR | MSN LABORATORIES LIMITED (IN) | 2013-08-01 | — | — | WO | claimed |
| EP-4217356-B1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-14 | — | — | EP | disclosed |
| US-20240101554-A1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-28 | — | — | US | disclosed |
| EP-4217356-A1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022064009-A1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-2867227-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-7420079-B2 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420079-B2 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| WO-2008081399-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20070207527-A1 | ENZYMATIC AMMONOLYSIS PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR DPP IV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070207527-A1 | ENZYMATIC AMMONOLYSIS PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR DPP IV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-7223573-B2 | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223573-B2 | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| WO-2005106011-A2 | PROCESS FOR PREPARING DIPEPTIDYL IV INHIBITORS AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2004052850-A2 | METHODS AND COMPOUNDS PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101554-A1 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | CDK7, CDK9, CDK1 | GLA 3022/4885MEN1 1849/4885KMT2A 661/4885 |
| US-20130204012-A1 | Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor | DNPEP, DPP4, PEPD | GLA 3582/4885MEN1 2318/4885KMT2A 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.